Akeso Boosts Revenue and R&D While Trimming Adjusted EBITDA Loss in 2025

Akeso, Inc. ( (HK:9926) ) just unveiled an update.

Akeso reported strong top-line growth for 2025, with revenue rising 43.9% year on year to RMB3.06 billion, driven largely by the initial inclusion of its first-in-class bispecific antibodies cadonilimab and ivonescimab in China’s National Reimbursement Drug List and contributions from new product launches. Despite a wider IFRS net loss of RMB1.14 billion, the company narrowed its non-IFRS adjusted EBITDA loss while ramping up investment in highly productive research and development.

Management highlighted improved operating efficiency in 2025, with lower ratios of sales and marketing, R&D, and general and administrative expenses compared with 2024. Akeso advanced multiple Phase III programs and pushed novel bispecifics into new areas such as antibody-drug conjugates, immune-related diseases and central nervous system disorders, underscoring an aggressive innovation strategy that could strengthen its competitive position in the global biologics market over time.

The most recent analyst rating on (HK:9926) stock is a Hold with a HK$130.00 price target. To see the full list of analyst forecasts on Akeso, Inc. stock, see the HK:9926 Stock Forecast page.

More about Akeso, Inc.

Akeso, Inc. is a Cayman Islands-incorporated biopharmaceutical company focused on bispecific antibody therapies. Positioned as a leading player in this segment, it develops and commercializes innovative treatments, including global first-in-class bispecific antibodies for cancers such as relapsed or metastatic cervical cancer and EGFR-mutated non-squamous non-small cell lung cancer, targeting both domestic and international markets.

Average Trading Volume: 6,506,731

Technical Sentiment Signal: Strong Buy

Current Market Cap: HK$112.2B

For an in-depth examination of 9926 stock, go to TipRanks’ Overview page.